Rating Change
Morgan Stanley analysts reiterated a Overweight rating on BioNTech SE (NASDAQ:BNTX) on July 08, 2026.
reiterateNASDAQ:BNTX
Morgan Stanley Reiterates Overweight Rating on BioNTech SE (BNTX)
Rating Change Morgan Stanley analysts reiterated a Overweight rating on BioNTech SE (NASDAQ:BNTX) on July 08, 2026. Market Context BioNTech SE operates in the Healthcare sector.…
Market Context
BioNTech SE operates in the Healthcare sector. The stock currently trades at $93.53 with a market capitalization of $23.1B.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for BioNTech SE.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for BioNTech SE
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 08, 2026 | Morgan Stanley | Overweight | N/A |
| May 27, 2026 | UBS | Buy | N/A |
| May 22, 2026 | Bernstein | Market Perform | N/A |
| May 06, 2026 | Wells Fargo | Overweight | N/A |
| May 06, 2026 | Canaccord Genuity | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View BNTX Stock Page
Frequently Asked Questions
What does a Overweight rating mean for BNTX?
A Overweight rating from Morgan Stanley reflects the analyst's outlook on BioNTech SE (NASDAQ:BNTX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BNTX forecast page.
